Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Research & Development (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Research & Development for 5 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 31.43% to $4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.4 million, a 58.94% decrease, with the full-year FY2024 number at $43.8 million, down 8.88% from a year prior.
  • Research & Development was $4.0 million for Q3 2025 at Lyra Therapeutics, down from $5.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $18.2 million in Q1 2024 to a low of $4.0 million in Q3 2025.
  • A 5-year average of $9.2 million and a median of $9.5 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 78.3% in 2022, then plummeted 73.26% in 2025.
  • Lyra Therapeutics' Research & Development stood at $10.3 million in 2021, then decreased by 8.62% to $9.5 million in 2022, then rose by 29.79% to $12.3 million in 2023, then plummeted by 48.13% to $6.4 million in 2024, then crashed by 36.39% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Research & Development are $4.0 million (Q3 2025), $5.1 million (Q2 2025), and $4.9 million (Q1 2025).